The strength of this work consist in the stepwise approach of the study design that allowed us to investigate the loss of B4GALT1, considering both the expression and methylation status in CRC primary tumors, metastases, and blood compartments in a single study exploring its diagnostic, prognostic, and anti-EGFR therapy-predictive significance. The gene discussed is B4GALT1; the disease is colorectal carcinoma.